Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model

Journal article

Wu R. et al, (2023), British Journal of General Practice

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.

Journal article

Zhou J. et al, (2023), Pharmacoeconomics, 41, 547 - 559

A systematic review of the factors associated with suicide attempts among sexual-minority youth

Journal article

Wang XX. et al, (2023), The European Journal of Psychiatry, 37, 72 - 83



Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

Cost-effectiveness of statin therapy in categories of patients in the UK

Conference paper

Mihaylova B. et al, (2022), EUROPEAN HEART JOURNAL, 43, 2841 - 2841

Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database

Journal article

Guo M. et al, (2021), International Journal of Clinical Pharmacy, 43, 1508 - 1515

A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts


Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149

Incorporating future unrelated medical costs in cost-effectiveness analysis in China.

Journal article

Jiang S. et al, (2021), BMJ Glob Health, 6

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study

Journal article

Clay E. et al, (2019), Journal of Market Access & Health Policy, 7, 1667195 - 1667195

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

Journal article

Zhou J. et al, (2019), Journal of Market Access & Health Policy, 7, 1648973 - 1648973